Actively Recruiting
Clinical and Biomolecular Characteristics of Reminder-Focused Positive-Psychiatry in Adolescents With Posttraumatic Stress Disorder
Led by University of California, Los Angeles · Updated on 2026-03-27
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Posttraumatic stress disorder (PTSD) is a common neuropsychiatric condition affecting children and is linked to increased neurovascular inflammation, suicidality, and later mental health issues. Researchers are evaluating the clinical and biomolecular effects of Reminder Focused Positive Psychiatry (RFPP) in adolescents aged 11 to 15 with PTSD. This trial assesses how RFPP influences core PTSD symptoms, trauma reactivity, wellbeing, vascular function, inflammation, and gene expression compared to a control group. Participants will be randomly assigned to one of two groups: the RFPP group intervention or an attentional control group receiving relaxation therapy. Both groups undergo telehealth sessions twice weekly for six weeks. The RFPP intervention focuses on improving emotional regulation and adaptive coping with trauma reminders, while the control group receives progressive muscle relaxation, education about PTSD, and supportive psychotherapy. Parents also participate weekly for six weeks, receiving psychoeducation or group process interventions. Throughout the study, adolescents and their parents will complete neuropsychiatric assessments at baseline, 3, 6, and 24 weeks. Biological markers including vascular function, inflammation markers, and stress-related gene expression will be measured at baseline and after six weeks. The main outcomes include changes in PTSD symptoms, trauma reactivity, wellbeing, biological markers, and parent-child interaction quality. The total study duration for participants is 24 months, including long-term follow-up assessments.
CONDITIONS
Brief Title
Biomolecular Characteristics of Reminder-Focused Positive-Psychiatry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Boy or girl with documented PTSD
- Aged 11 to 15 years old
- Able to read and write in English
You will not qualify if you...
- Presence of intellectual disabilities
- Presence of psychotic or self-injurious behavior
- Presence of seizure disorder
- Presence of language disorder
- Presence of eye disorders
- Presence of other neurodevelopmental disorders
- Diagnosis of substance use disorder
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 weeks
Participants receive behavioral interventions focused on enhancing emotional regulation and coping strategies or relaxation therapy via telehealth.
Twice weekly telehealth sessions for 6 weeks
Duration - Up to 24 months
Participants are monitored to assess the impact of the interventions on PTSD symptoms, well-being, and biologic biomarkers.
Periodic follow-up visits over 24 months
Trial Site Locations
Total: 1 location
1
UCLA
Los Angeles, California, United States, 90024
Actively Recruiting
Research Team
N
Naser Ahmadi, MD PhD
N
Naser Ahmadi, MD PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here